Boosting the immune response against canine osteosarcoma using specialized immune cells
Official title: Generation of tumor specific immunity in canine osteosarcoma through dendritic cell hyperactivation
Funded at Tufts University Boston · NIH-11255126 · Data updated 2026-11-12
This study is looking at ways to boost the immune system in dogs with osteosarcoma by using special treatments that help important immune cells work better, with the hope that what they learn can also help improve cancer treatments for people.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Tufts University Boston NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | September 1, 2022 |
| Project end | August 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $76,725 |
| NIH project number | 3U01CA272268-03S1 |
| Project ID | NIH-11255126 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are dogs diagnosed with osteosarcoma who are eligible for immunotherapy treatments.
✕Less likely to help
Dogs with other types of cancer or those not diagnosed with osteosarcoma may not benefit from this research.
What this research studies
This research investigates how to enhance the immune response in dogs with osteosarcoma by hyperactivating dendritic cells, which are crucial for initiating T cell responses. The approach involves using a combination of tumor lysate and specific immune-stimulating agents to promote the migration and function of these cells. By studying this process in dogs, the researchers aim to create a model that closely resembles human cancers, potentially leading to better treatments for both species.
Why it matters
Potential benefit: If successful, this research could lead to more effective immunotherapies for dogs with osteosarcoma, improving their chances of recovery.
How similar studies have gone: Previous research has shown promise in using dendritic cell hyperactivation in other cancer models, suggesting potential for success in this approach.
Where this research is happening
-
Tufts University Boston
Boston, United States Active
Researchers
- Principal investigator: London, Cheryl a — Tufts University Boston
- Study coordinator: London, Cheryl a
Related research
Other NIH-funded projects on the same topics.
-
Understanding how bone cancer cells rely on certain pathways to grow in childhood osteosarcoma
This grant studies how specific cancer-related pathways in bone-forming cells drive osteosarcoma in children, with the aim of finding better treatments.
-
Histotripsy + immune boost to fight osteosarcoma
A new treatment idea combines a precise non-surgical ultrasound method with an immune-boosting compound to help fight bone cancer in people and dogs.
-
Genomically guided drug testing for osteosarcoma in patient-derived models
A precision approach tests new drugs on osteosarcoma models created from patients to find promising treatments for kids and teens.
-
New ways to stop osteosarcoma from spreading
Researchers are testing new approaches to block how osteosarcoma spreads, with the aim of improving survival for children and adults with metastatic disease.
-
Targeting OST Redundancy to Treat Osteosarcoma
A study in people with advanced bone cancer to see if new OST-targeting drugs can slow or stop tumor growth.
-
Focal Adhesion Kinase inhibitor to block osteosarcoma spread to the lungs
A cancer treatment plan tests whether blocking a specific cell signal can stop osteosarcoma from growing and spreading to the lungs in kids and young people.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.